HotSpot Therapeutics - About the company
HotSpot Therapeutics is a series C company based in Boston (United States), founded in 2017 by Geraldine Harriman. It operates as a Developer of a platform for protein function analysis. HotSpot Therapeutics has raised $210M in funding from investors like Atlas Venture, SR One and Pivotal bioVenture Partners. The company has 158 active competitors, including 38 funded and 15 that have exited. Its top competitors include companies like Certara, Cartography Biosciences and Astex Pharmaceuticals.
Company Details
HotSpot Therapeutics offers a proprietary platform for protein structure-function analysis. The company has developed the proprietary technology platform used to analyze the allosteric druggable sites on the regulatory proteins required for its function using novel compounds.
- Website
- www.hotspotthera.com/
- Social
- Email ID
- *****@hotspotthera.com
- Phone Number
- +1 **********
- Registered Address
- Boston, Massachusetts
Key Metrics
Founded Year
2017
Location
Boston, United States
Stage
Series C
Total Funding
$210M in 3 rounds
Latest Funding Round
Investors
Ranked
16th among 158 active competitors
Employee Count
59 as on Aug 31, 2026
Legal entities associated with HotSpot Therapeutics
HotSpot Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
HOTSPOT THERAPEUTICS INC CIN: 815033388 , United States, Active | Dec 31, 2016 | - | 38 (As on Dec 31, 2024) | - |
Sign up to download HotSpot Therapeutics' company profile
HotSpot Therapeutics's funding and investors
HotSpot Therapeutics has raised a total funding of $210M over 3 rounds. Its first funding round was on Jul 17, 2018. Its latest funding round was a Series C round on Nov 29, 2021 for $*****. 10 investors participated in its latest round. HotSpot Therapeutics has 16 institutional investors.
Here is the list of recent funding rounds of HotSpot Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 29, 2021 | 9519672 | Series C | 2294062 | 9777488 | 2201806 | 9321522 |
May 21, 2020 | 3537523 | Series B | 9646499 | 9258584 | 3331479 | |
Jul 17, 2018 | 9192362 | Series A | 1581322 | 5073768 | 9346997 |
Access funding benchmarks and valuations. Sign up today!View details of HotSpot Therapeutics's funding rounds and investors
HotSpot Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of HotSpot Therapeutics is Geraldine Harriman.
Here are the details of HotSpot Therapeutics' key team members:
- Geraldine Harriman: Co-Founder of HotSpot Therapeutics.
View details of HotSpot Therapeutics's Founder profiles and Board Members
HotSpot Therapeutics' employee count trend
HotSpot Therapeutics has 59 employees as of Aug 26. Here is HotSpot Therapeutics's employee count trend over the years:
Uncover HotSpot Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
HotSpot Therapeutics's Competitors and alternates
Top competitors of HotSpot Therapeutics include Certara, Cartography Biosciences and Astex Pharmaceuticals. Here is the list of Top 10 competitors of HotSpot Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Certara 2008, Princeton (United States), Public | Provider of a platform for in silico drug discovery and consulting services | - | 65/100 | |
2nd |  Cartography Biosciences 2020, Foster City (United States), Series B | Provider of a platform to discover immunotherapeutics | $124M | 63/100 | |
3rd | Astex Pharmaceuticals 1991, Pleasanton (United States), Acquired | Oncology and CNS drug discovery and development using cutting-edge technology | $3M | 60/100 | |
4th | Pharmacelera 2015, Barcelona (Spain), Series A | Hardware and software solutions for computer-aided drug design | $7.1M | 59/100 | |
5th | Oxford Drug Design 2001, Oxford (United Kingdom), Series A | Provider of computer-aided design of antibiotics for MDR infections | $12.4M | 59/100 | |
6th |  Inpharmatica 1998, London (United Kingdom), Acquired | Developer of predictive informatics based platform for drug discovery | $75M | 58/100 | |
7th | Genialis 2015, Boston (United States), Series A | Developer of end-to-end bioinformatics software solutions | $16M | 56/100 | |
8th | CytoReason 2016, Haifa (Israel), Series C | Discovering immune system based drugs by biological data analytics | $130M | 55/100 | |
9th |  Probius 2016, Fremont (United States), Seed | Digital biochemical analysis tool for healthcare researchers | $2.44M | 53/100 | |
10th | AI-based precision medicine supporting tool for drug discovery | - | 51/100 | ||
16th |  HotSpot Therapeutics 2017, Boston (United States), Series C | Developer of a platform for protein function analysis | $210M | 45/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on HotSpot Therapeutics's competitors? Click here to see the top ones
HotSpot Therapeutics's Investments and acquisitions
HotSpot Therapeutics has made no investments or acquisitions yet.
Reports related to HotSpot Therapeutics
Here is the latest report on HotSpot Therapeutics's sector:
News related to HotSpot Therapeutics
Filter this list•
HotSpot Therapeutics Presents CBM Signalosome Inhibitor Preclinical Data at ESMO Gastrointestinal Cancers Congress 2025PR Newswire•Jul 04, 2025•HotSpot Therapeutics
•
HotSpot Therapeutics Presents IRF5 Preclinical Data at FOCIS 2025PR Newswire•Jun 26, 2025•HotSpot Therapeutics
•
Hotspot signs Memorandum with Clear Blue led Consortium to AccessibilityGlobeNewswire•Mar 04, 2025•Hotspot Network, Clear Blue Technologies, HotSpot Therapeutics, Empower New Energy and 1 other
•
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024PR Newswire•Sep 13, 2024•HotSpot Therapeutics
•
HotSpot doses first advanced solid tumour patient in Phase I/II studyclinicaltrialsarena.com•Apr 12, 2023•HotSpot Therapeutics
•
HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-BPR Newswire•Jan 03, 2023•HotSpot Therapeutics
•
AbbVie and HotSpot sign partnership for autoimmune disease therapyPharmaceutical Technology•Dec 07, 2022•AbbVie, HotSpot Therapeutics
•
AbbVie offers up to $335M for connection with HotSpot's preclinical small-molecule programFierce Biotech•Dec 06, 2022•AbbVie, HotSpot Therapeutics
•
Excelra, HotSpot Therapeutics partner for treatment of cancer, autoimmune diseaseBioSpectrum India•May 26, 2022•HotSpot Therapeutics, Excelra
•
Caris Life Sciences and HotSpot Therapeutics AnnounceMedical Device News•Jan 10, 2022•HotSpot Therapeutics, Caris Life Sciences
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about HotSpot Therapeutics
Explore our recently published companies
- Minerva Capital Fund - Hungary based, 2012 founded, Unfunded company
- Mhanimalfoods - Unfunded company
- p-didakt - Hamburg based, 1883 founded, Unfunded company
- MOOD Publishing - Denmark based, 2019 founded, Unfunded company
- Lynne Azpeitia - 2021 founded, Unfunded company
- Krafted Online - San Francisco based, Unfunded company
